Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.
Identifieur interne : 000411 ( Main/Exploration ); précédent : 000410; suivant : 000412Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.
Auteurs : Diego Viasus [Espagne] ; José Ram N Pa O-Pardo ; Elisa Cordero ; Antoni Campins ; Francisco L Pez-Medrano ; Aroa Villoslada ; Maria C. Fari As ; Asunci N Moreno ; Jesús Rodríguez-Ba O ; José Antonio Oteo ; Joaquín Martínez-Montauti ; Julián Torre-Cisneros ; Ferrán Segura ; Jordi CarratalàSource :
- The Journal of infection [ 1532-2742 ] ; 2011.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse de survie (MeSH), Espagne (MeSH), Facteurs immunologiques (administration et posologie), Femelle (MeSH), Grippe humaine (complications), Grippe humaine (mortalité), Grippe humaine (thérapie), Grippe humaine (virologie), Hormones corticosurrénaliennes (administration et posologie), Humains (MeSH), Immunomodulation (MeSH), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie), Macrolides (administration et posologie), Mâle (MeSH), Pneumopathie bactérienne (immunologie), Pneumopathie bactérienne (mortalité), Pneumopathie bactérienne (thérapie), Résultat thérapeutique (MeSH), Soins de réanimation (statistiques et données numériques), Sous-type H1N1 du virus de la grippe A (isolement et purification), Études prospectives (MeSH).
- MESH :
- administration et posologie : Facteurs immunologiques, Hormones corticosurrénaliennes, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Macrolides.
- immunologie : Pneumopathie bactérienne.
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- mortalité : Grippe humaine, Pneumopathie bactérienne.
- statistiques et données numériques : Soins de réanimation.
- thérapie : Grippe humaine, Pneumopathie bactérienne.
- virologie : Grippe humaine.
- Adulte, Adulte d'âge moyen, Analyse de survie, Espagne, Femelle, Grippe humaine, Humains, Immunomodulation, Mâle, Résultat thérapeutique, Études prospectives.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (administration & dosage), Adult (MeSH), Critical Care (statistics & numerical data), Female (MeSH), Humans (MeSH), Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage), Immunologic Factors (administration & dosage), Immunomodulation (MeSH), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza, Human (complications), Influenza, Human (mortality), Influenza, Human (therapy), Influenza, Human (virology), Macrolides (administration & dosage), Male (MeSH), Middle Aged (MeSH), Pneumonia, Bacterial (immunology), Pneumonia, Bacterial (mortality), Pneumonia, Bacterial (therapy), Prospective Studies (MeSH), Spain (MeSH), Survival Analysis (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Adrenal Cortex Hormones, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Immunologic Factors, Macrolides.
- geographic : Spain.
- complications : Influenza, Human.
- immunology : Pneumonia, Bacterial.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- mortality : Influenza, Human, Pneumonia, Bacterial.
- statistics & numerical data : Critical Care.
- therapy : Influenza, Human, Pneumonia, Bacterial.
- virology : Influenza, Human.
- Adult, Female, Humans, Immunomodulation, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome.
Abstract
OBJECTIVE
To determine the effect of immunomodulatory therapies on the development of severe disease in hospitalized adults with laboratory-confirmed pandemic influenza A (H1N1) 2009 complicated by pneumonia.
METHODS
Observational, prospective cohort study at thirteen tertiary hospitals in Spain. The use of corticosteroids, macrolides and statins was recorded. The outcome of interest was severe disease, defined as the composite of intensive care unit admission or death after the first day of hospitalization.
RESULTS
Of the 197 patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia, 68 (34.5%) received some anti-inflammatory therapy since hospital admission (corticosteroids in 37, macrolides in 31 and statins in 12). Severe disease occurred in 29 (14.7%) patients. After adjustment for confounding factors, immunomodulatory therapies as a group were not associated with a lower risk for developing severe disease (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.22-1.86). In a further a priori analysis, corticosteroids, macrolides and statins were included in a multivariate model. None of these therapies was found to be associated with a lower risk for developing severe disease.
CONCLUSIONS
Immunomodulatory therapies use since hospital admission did not prevent the development of severe disease in adults with pandemic influenza A (H1N1) 2009 complicated by pneumonia.
DOI: 10.1016/j.jinf.2011.01.014
PubMed: 21295604
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.</title><author><name sortKey="Viasus, Diego" sort="Viasus, Diego" uniqKey="Viasus D" first="Diego" last="Viasus">Diego Viasus</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases, Hospital Universitari de Bellvitge, University of Barcelona, Feixa Llarga s/n, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Infectious Diseases, Hospital Universitari de Bellvitge, University of Barcelona, Feixa Llarga s/n, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pa O Pardo, Jose Ram N" sort="Pa O Pardo, Jose Ram N" uniqKey="Pa O Pardo J" first="José Ram N" last="Pa O-Pardo">José Ram N Pa O-Pardo</name></author><author><name sortKey="Cordero, Elisa" sort="Cordero, Elisa" uniqKey="Cordero E" first="Elisa" last="Cordero">Elisa Cordero</name></author><author><name sortKey="Campins, Antoni" sort="Campins, Antoni" uniqKey="Campins A" first="Antoni" last="Campins">Antoni Campins</name></author><author><name sortKey="L Pez Medrano, Francisco" sort="L Pez Medrano, Francisco" uniqKey="L Pez Medrano F" first="Francisco" last="L Pez-Medrano">Francisco L Pez-Medrano</name></author><author><name sortKey="Villoslada, Aroa" sort="Villoslada, Aroa" uniqKey="Villoslada A" first="Aroa" last="Villoslada">Aroa Villoslada</name></author><author><name sortKey="Fari As, Maria C" sort="Fari As, Maria C" uniqKey="Fari As M" first="Maria C" last="Fari As">Maria C. Fari As</name></author><author><name sortKey="Moreno, Asunci N" sort="Moreno, Asunci N" uniqKey="Moreno A" first="Asunci N" last="Moreno">Asunci N Moreno</name></author><author><name sortKey="Rodriguez Ba O, Jesus" sort="Rodriguez Ba O, Jesus" uniqKey="Rodriguez Ba O J" first="Jesús" last="Rodríguez-Ba O">Jesús Rodríguez-Ba O</name></author><author><name sortKey="Oteo, Jose Antonio" sort="Oteo, Jose Antonio" uniqKey="Oteo J" first="José Antonio" last="Oteo">José Antonio Oteo</name></author><author><name sortKey="Martinez Montauti, Joaquin" sort="Martinez Montauti, Joaquin" uniqKey="Martinez Montauti J" first="Joaquín" last="Martínez-Montauti">Joaquín Martínez-Montauti</name></author><author><name sortKey="Torre Cisneros, Julian" sort="Torre Cisneros, Julian" uniqKey="Torre Cisneros J" first="Julián" last="Torre-Cisneros">Julián Torre-Cisneros</name></author><author><name sortKey="Segura, Ferran" sort="Segura, Ferran" uniqKey="Segura F" first="Ferrán" last="Segura">Ferrán Segura</name></author><author><name sortKey="Carratala, Jordi" sort="Carratala, Jordi" uniqKey="Carratala J" first="Jordi" last="Carratalà">Jordi Carratalà</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21295604</idno><idno type="pmid">21295604</idno><idno type="doi">10.1016/j.jinf.2011.01.014</idno><idno type="wicri:Area/Main/Corpus">00403</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00403</idno><idno type="wicri:Area/Main/Curation">000403</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000403</idno><idno type="wicri:Area/Main/Exploration">000403</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.</title><author><name sortKey="Viasus, Diego" sort="Viasus, Diego" uniqKey="Viasus D" first="Diego" last="Viasus">Diego Viasus</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases, Hospital Universitari de Bellvitge, University of Barcelona, Feixa Llarga s/n, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Infectious Diseases, Hospital Universitari de Bellvitge, University of Barcelona, Feixa Llarga s/n, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pa O Pardo, Jose Ram N" sort="Pa O Pardo, Jose Ram N" uniqKey="Pa O Pardo J" first="José Ram N" last="Pa O-Pardo">José Ram N Pa O-Pardo</name></author><author><name sortKey="Cordero, Elisa" sort="Cordero, Elisa" uniqKey="Cordero E" first="Elisa" last="Cordero">Elisa Cordero</name></author><author><name sortKey="Campins, Antoni" sort="Campins, Antoni" uniqKey="Campins A" first="Antoni" last="Campins">Antoni Campins</name></author><author><name sortKey="L Pez Medrano, Francisco" sort="L Pez Medrano, Francisco" uniqKey="L Pez Medrano F" first="Francisco" last="L Pez-Medrano">Francisco L Pez-Medrano</name></author><author><name sortKey="Villoslada, Aroa" sort="Villoslada, Aroa" uniqKey="Villoslada A" first="Aroa" last="Villoslada">Aroa Villoslada</name></author><author><name sortKey="Fari As, Maria C" sort="Fari As, Maria C" uniqKey="Fari As M" first="Maria C" last="Fari As">Maria C. Fari As</name></author><author><name sortKey="Moreno, Asunci N" sort="Moreno, Asunci N" uniqKey="Moreno A" first="Asunci N" last="Moreno">Asunci N Moreno</name></author><author><name sortKey="Rodriguez Ba O, Jesus" sort="Rodriguez Ba O, Jesus" uniqKey="Rodriguez Ba O J" first="Jesús" last="Rodríguez-Ba O">Jesús Rodríguez-Ba O</name></author><author><name sortKey="Oteo, Jose Antonio" sort="Oteo, Jose Antonio" uniqKey="Oteo J" first="José Antonio" last="Oteo">José Antonio Oteo</name></author><author><name sortKey="Martinez Montauti, Joaquin" sort="Martinez Montauti, Joaquin" uniqKey="Martinez Montauti J" first="Joaquín" last="Martínez-Montauti">Joaquín Martínez-Montauti</name></author><author><name sortKey="Torre Cisneros, Julian" sort="Torre Cisneros, Julian" uniqKey="Torre Cisneros J" first="Julián" last="Torre-Cisneros">Julián Torre-Cisneros</name></author><author><name sortKey="Segura, Ferran" sort="Segura, Ferran" uniqKey="Segura F" first="Ferrán" last="Segura">Ferrán Segura</name></author><author><name sortKey="Carratala, Jordi" sort="Carratala, Jordi" uniqKey="Carratala J" first="Jordi" last="Carratalà">Jordi Carratalà</name></author></analytic><series><title level="j">The Journal of infection</title><idno type="eISSN">1532-2742</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (administration & dosage)</term><term>Adult (MeSH)</term><term>Critical Care (statistics & numerical data)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)</term><term>Immunologic Factors (administration & dosage)</term><term>Immunomodulation (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza, Human (complications)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (therapy)</term><term>Influenza, Human (virology)</term><term>Macrolides (administration & dosage)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pneumonia, Bacterial (immunology)</term><term>Pneumonia, Bacterial (mortality)</term><term>Pneumonia, Bacterial (therapy)</term><term>Prospective Studies (MeSH)</term><term>Spain (MeSH)</term><term>Survival Analysis (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse de survie (MeSH)</term><term>Espagne (MeSH)</term><term>Facteurs immunologiques (administration et posologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (complications)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (thérapie)</term><term>Grippe humaine (virologie)</term><term>Hormones corticosurrénaliennes (administration et posologie)</term><term>Humains (MeSH)</term><term>Immunomodulation (MeSH)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie)</term><term>Macrolides (administration et posologie)</term><term>Mâle (MeSH)</term><term>Pneumopathie bactérienne (immunologie)</term><term>Pneumopathie bactérienne (mortalité)</term><term>Pneumopathie bactérienne (thérapie)</term><term>Résultat thérapeutique (MeSH)</term><term>Soins de réanimation (statistiques et données numériques)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Études prospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term><term>Immunologic Factors</term><term>Macrolides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Facteurs immunologiques</term><term>Hormones corticosurrénaliennes</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Macrolides</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Critical Care</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Soins de réanimation</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Immunomodulation</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Espagne</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Immunomodulation</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To determine the effect of immunomodulatory therapies on the development of severe disease in hospitalized adults with laboratory-confirmed pandemic influenza A (H1N1) 2009 complicated by pneumonia.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Observational, prospective cohort study at thirteen tertiary hospitals in Spain. The use of corticosteroids, macrolides and statins was recorded. The outcome of interest was severe disease, defined as the composite of intensive care unit admission or death after the first day of hospitalization.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Of the 197 patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia, 68 (34.5%) received some anti-inflammatory therapy since hospital admission (corticosteroids in 37, macrolides in 31 and statins in 12). Severe disease occurred in 29 (14.7%) patients. After adjustment for confounding factors, immunomodulatory therapies as a group were not associated with a lower risk for developing severe disease (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.22-1.86). In a further a priori analysis, corticosteroids, macrolides and statins were included in a multivariate model. None of these therapies was found to be associated with a lower risk for developing severe disease.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Immunomodulatory therapies use since hospital admission did not prevent the development of severe disease in adults with pandemic influenza A (H1N1) 2009 complicated by pneumonia.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21295604</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J. Infect.</ISOAbbreviation></Journal><ArticleTitle>Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.</ArticleTitle><Pagination><MedlinePgn>193-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2011.01.014</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the effect of immunomodulatory therapies on the development of severe disease in hospitalized adults with laboratory-confirmed pandemic influenza A (H1N1) 2009 complicated by pneumonia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Observational, prospective cohort study at thirteen tertiary hospitals in Spain. The use of corticosteroids, macrolides and statins was recorded. The outcome of interest was severe disease, defined as the composite of intensive care unit admission or death after the first day of hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 197 patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia, 68 (34.5%) received some anti-inflammatory therapy since hospital admission (corticosteroids in 37, macrolides in 31 and statins in 12). Severe disease occurred in 29 (14.7%) patients. After adjustment for confounding factors, immunomodulatory therapies as a group were not associated with a lower risk for developing severe disease (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.22-1.86). In a further a priori analysis, corticosteroids, macrolides and statins were included in a multivariate model. None of these therapies was found to be associated with a lower risk for developing severe disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immunomodulatory therapies use since hospital admission did not prevent the development of severe disease in adults with pandemic influenza A (H1N1) 2009 complicated by pneumonia.</AbstractText><CopyrightInformation>Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viasus</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Universitari de Bellvitge, University of Barcelona, Feixa Llarga s/n, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paño-Pardo</LastName><ForeName>José Ramón</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Cordero</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Campins</LastName><ForeName>Antoni</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>López-Medrano</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Villoslada</LastName><ForeName>Aroa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fariñas</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Asunción</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rodríguez-Baño</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Oteo</LastName><ForeName>José Antonio</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Martínez-Montauti</LastName><ForeName>Joaquín</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Torre-Cisneros</LastName><ForeName>Julián</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Segura</LastName><ForeName>Ferrán</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Carratalà</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><CollectiveName>Novel Influenza A (H1N1) Study Group, Spanish Network for Research in Infectious Diseases</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018942">Macrolides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="Y">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018410" MajorTopicYN="N">Pneumonia, Bacterial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Gudiol</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niubo</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martín-Quirós</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romero-Gómez</LastName><ForeName>María</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martínez-Sánchez</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueira</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prados</LastName><ForeName>María Concepción</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pachón</LastName><ForeName>Jerónimo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>García-Cabrera</LastName><ForeName>Emilio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riera</LastName><ForeName>Melchor</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguado</LastName><ForeName>José María</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vila</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payeras</LastName><ForeName>Antoni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>García-Gasalla</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>González-Fernández</LastName><ForeName>José Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutiérrez-Cuadra</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanjuan</LastName><ForeName>María Victoria</ForeName><Initials>MV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parra</LastName><ForeName>José Antonio</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linares</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoyo</LastName><ForeName>Irma</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcos</LastName><ForeName>María Angeles</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pumarola</LastName><ForeName>Tomás</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Cueto</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Domínguez</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gálvez</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pérez-Martínez</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanco</LastName><ForeName>José R</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanz</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metola</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibarra</LastName><ForeName>Valvenera</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortega</LastName><ForeName>Lucía</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lara</LastName><ForeName>Rosario</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Causse</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutiérrez-Aroca</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivero</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Navarro</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>González</LastName><ForeName>Eva María</ForeName><Initials>EM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21295604</ArticleId><ArticleId IdType="pii">S0163-4453(11)00028-4</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2011.01.014</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><noCountry><name sortKey="Campins, Antoni" sort="Campins, Antoni" uniqKey="Campins A" first="Antoni" last="Campins">Antoni Campins</name><name sortKey="Carratala, Jordi" sort="Carratala, Jordi" uniqKey="Carratala J" first="Jordi" last="Carratalà">Jordi Carratalà</name><name sortKey="Cordero, Elisa" sort="Cordero, Elisa" uniqKey="Cordero E" first="Elisa" last="Cordero">Elisa Cordero</name><name sortKey="Fari As, Maria C" sort="Fari As, Maria C" uniqKey="Fari As M" first="Maria C" last="Fari As">Maria C. Fari As</name><name sortKey="L Pez Medrano, Francisco" sort="L Pez Medrano, Francisco" uniqKey="L Pez Medrano F" first="Francisco" last="L Pez-Medrano">Francisco L Pez-Medrano</name><name sortKey="Martinez Montauti, Joaquin" sort="Martinez Montauti, Joaquin" uniqKey="Martinez Montauti J" first="Joaquín" last="Martínez-Montauti">Joaquín Martínez-Montauti</name><name sortKey="Moreno, Asunci N" sort="Moreno, Asunci N" uniqKey="Moreno A" first="Asunci N" last="Moreno">Asunci N Moreno</name><name sortKey="Oteo, Jose Antonio" sort="Oteo, Jose Antonio" uniqKey="Oteo J" first="José Antonio" last="Oteo">José Antonio Oteo</name><name sortKey="Pa O Pardo, Jose Ram N" sort="Pa O Pardo, Jose Ram N" uniqKey="Pa O Pardo J" first="José Ram N" last="Pa O-Pardo">José Ram N Pa O-Pardo</name><name sortKey="Rodriguez Ba O, Jesus" sort="Rodriguez Ba O, Jesus" uniqKey="Rodriguez Ba O J" first="Jesús" last="Rodríguez-Ba O">Jesús Rodríguez-Ba O</name><name sortKey="Segura, Ferran" sort="Segura, Ferran" uniqKey="Segura F" first="Ferrán" last="Segura">Ferrán Segura</name><name sortKey="Torre Cisneros, Julian" sort="Torre Cisneros, Julian" uniqKey="Torre Cisneros J" first="Julián" last="Torre-Cisneros">Julián Torre-Cisneros</name><name sortKey="Villoslada, Aroa" sort="Villoslada, Aroa" uniqKey="Villoslada A" first="Aroa" last="Villoslada">Aroa Villoslada</name></noCountry><country name="Espagne"><region name="Catalogne"><name sortKey="Viasus, Diego" sort="Viasus, Diego" uniqKey="Viasus D" first="Diego" last="Viasus">Diego Viasus</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21295604
|texte= Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21295604" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |